ABIOMED Inc
Change company Symbol lookup
Select an option...
ABMD ABIOMED Inc
BAC Bank of America Corp
KVHI KVH Industries Inc
BHC Bausch Health Companies Inc
ANPC AnPac Bio-Medical Science Co Ltd
TREX Trex Company Inc
VIVO Meridian Bioscience Inc
WASH Washington Trust Bancorp Inc
AWF AllianceBernstein Global High Income Fund Inc.
AVK Advent Convertible & Income Fund
Go

Health Care : Health Care Equipment & Supplies | Mid Cap Growth
Company profile

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Premarket

Last Trade
Delayed
$280.51
-0.91 (-0.32%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$281.42
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
455

10-day average volume:
224,148
455

Display:

Providers:

UpdateCancel
6 providers
Today's News, October 26, 2020
FDA Grants 510(k) Clearance for Abiomed's Innovative Cardiopulmonary Support Technology

The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System(TM). (BusinessWire)

October 16, 2020
Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP

Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates...(BusinessWire)

Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women

Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The findings were presented at TCT Connect, the 32nd annual scientific symposium of the...(BusinessWire)

October 15, 2020
Abiomed to Host a Virtual Meeting to Discuss New Clinical Data Presented at TCT Connect

Abiomed, Inc. (NASDAQ: ABMD) announced it will host a virtual investor meeting on Tuesday, October 20, 2020 at 8:00 a.m. EDT to review new clinical data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research...(BusinessWire)

Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes

Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat procedures) when Impella is used to achieve a more complete revascularization in a...(BusinessWire)

October 14, 2020
Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella-supported high-risk PCI, is associated with significant improvement of left ventricular ejection fraction...(BusinessWire)

October 08, 2020
Abiomed Second Quarter Fiscal 2021 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October 29, 2020, the Company will release financial results for the second quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, October 29, 2020...(BusinessWire)

TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients

The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock...(BusinessWire)

September 30, 2020
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors

Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves...(Globe Newswire)

September 14, 2020
Abiomed to Hold Fireside Chat at the Raymond James North American Equities Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Raymond James North American...(BusinessWire)

September 08, 2020
Abiomed to Hold Fireside Chat at the 18th Annual Morgan Stanley Global Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the 18th Annual Morgan Stanley Global...(BusinessWire)

August 06, 2020
Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 2021 revenue of $164.9 million compared to revenue of $207.7 million for the same period of fiscal 2020 despite a...(BusinessWire)

August 04, 2020
FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients

The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and...(BusinessWire)

July 30, 2020
Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart Pump

A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock patients. The historic survival rate for...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.